Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pioglitazone
Drug ID BADD_D01777
Description Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence.[L11416] The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose[L11416] via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ).[A19757] PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.[A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.[L11461]
Indications and Usage Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].
Marketing Status Prescription
ATC Code A10BG03
DrugBank ID DB01132
KEGG ID D08378
MeSH ID D000077205
PubChem ID 4829
TTD Drug ID D03OFF
NDC Product Code 57237-219; 68071-4964; 50090-2390; 70771-1021; 68071-4959; 50090-4605; 50090-4556; 61919-781; 50090-4780; 50090-2401; 68071-2264; 11532-0011; 68071-2373; 0781-5420; 71335-1298; 68382-306; 70518-2609; 43547-427; 64764-451; 71335-1137; 68071-5155; 68382-307; 60687-391; 33342-056; 57237-221; 72189-293; 68788-7514; 0093-7273; 50090-4586; 70771-1022; 71335-1385; 33342-055; 50090-1321; 68382-308; 16729-020; 70518-2129; 64764-151; 16729-022; 68071-1621; 68788-7511; 0093-7271; 53002-2757; 16729-021; 68071-2437; 70518-2431; 68788-7989; 33342-054; 71335-1659; 0093-7272; 71335-1333; 53002-2755; 71335-0088; 72189-105; 0781-5422; 71335-1759; 70771-1023; 43547-428; 53002-2756; 11532-0013; 68071-5080; 0904-7096; 64764-301; 71610-495; 0904-7090; 70934-619; 0781-5421; 68071-2495; 11532-0012; 57237-220; 43547-426
Synonyms Pioglitazone | 5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione | U 72107A | U72,107A | U-72107A | U72107A | AD 4833 | AD-4833 | AD4833 | Pioglitazone Hydrochloride | Actos
Chemical Information
Molecular Formula C19H20N2O3S
CAS Registry Number 111025-46-8
SMILES CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ovarian cancer21.11.01.003; 16.12.04.0010.000150%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pancreatic carcinoma16.13.10.001; 07.21.09.0020.000301%Not Available
Pemphigoid23.03.01.004; 10.04.02.002--Not Available
Pericardial effusion02.06.01.002--
Pericarditis02.06.02.001--
Pharyngitis11.01.13.003; 07.05.07.004; 22.07.03.004--
Plasma cell myeloma16.23.02.004; 01.14.02.004--Not Available
Platelet count decreased13.01.04.001--
Pleural effusion22.05.02.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.007--
Polyuria20.02.03.0020.000100%Not Available
Pregnancy18.08.02.004--Not Available
Proteinuria20.02.01.011--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.006--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyelonephritis20.01.09.001; 11.01.14.0020.000384%Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal cancer20.01.04.002; 16.08.02.0010.000501%Not Available
Renal cyst20.01.04.001; 16.27.01.0010.000384%Not Available
Renal disorder20.01.02.002--Not Available
Renal failure20.01.03.005--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Retinal detachment06.09.03.003; 12.01.04.0040.000384%
Rhabdomyolysis15.05.05.002--
Sepsis11.01.11.003--
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages